SUN PHARMACEUTICAL IND L vs VIMTA LABS LIMITED

A side-by-side comparison of SUN PHARMACEUTICAL IND L (SUNPHARMA) and VIMTA LABS LIMITED (VIMTALABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SUNPHARMA vs VIMTALABS on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

40.40
P/E ratio
36.96
5.57
P/B ratio
5.47
0.83%
Dividend yield
0.36%
₹47.84
EPS
₹15.13

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
12.83%
21.00%
Return on capital
25.00%
30.00%
EBITDA margin
35.00%
19.69%
Net margin
19.48%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
8.98%
10.57%
Profit CAGR (3Y)
18.15%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.64L Cr
Market cap
₹2,514 Cr
₹58,462 Cr
Revenue
₹344 Cr
₹11,509 Cr
Net profit
₹67 Cr
0.06
Debt / equity
0.01
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
VIMTA LABS LIMITED
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 30.0% CAGR over last 5 years"]
SUN PHARMACEUTICAL IND L full analysis VIMTA LABS LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

SUN PHARMACEUTICAL IND L vs VIMTA LABS LIMITED: Share Price, Valuation & Which to Buy | DocStoX